GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » EBIT

Alk-Abello AS (OCSE:ALK B) EBIT : kr1,083 Mil (TTM As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello AS EBIT?

Alk-Abello AS's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was kr306 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was kr1,083 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alk-Abello AS's annualized ROC % for the quarter that ended in Sep. 2024 was 16.54%. Alk-Abello AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 31.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alk-Abello AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.20%.


Alk-Abello AS EBIT Historical Data

The historical data trend for Alk-Abello AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS EBIT Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 135.00 302.00 471.00 669.00

Alk-Abello AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.00 197.00 316.00 264.00 306.00

Competitive Comparison of Alk-Abello AS's EBIT

For the Biotechnology subindustry, Alk-Abello AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's EV-to-EBIT falls into.



Alk-Abello AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,083 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alk-Abello AS  (OCSE:ALK B) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alk-Abello AS's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=1224 * ( 1 - 24.56% )/( (5569 + 5594)/ 2 )
=923.3856/5581.5
=16.54 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Alk-Abello AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1224/( ( (2273 + max(1535, 0)) + (2258 + max(1596, 0)) )/ 2 )
=1224/( ( 3808 + 3854 )/ 2 )
=1224/3831
=31.95 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(846 + 1593 + 185) - (1056 + 0 + 33)
=1535

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(861 + 1608 + 150) - (999 + 0 + 24)
=1596

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alk-Abello AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=1083/33848.352
=3.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alk-Abello AS EBIT Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines